MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
6.52
+0.24
+3.74%
Opening 14:34 06/24 EDT
OPEN
6.36
PREV CLOSE
6.28
HIGH
6.71
LOW
6.36
VOLUME
155.81K
TURNOVER
--
52 WEEK HIGH
10.42
52 WEEK LOW
3.475
MARKET CAP
351.05M
P/E (TTM)
-9.2241
1D
5D
1M
3M
1Y
5Y
1D
DiaMedica Therapeutics announces dosing of first two patients in DM199 study
TipRanks · 1d ago
Analysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN)
TipRanks · 1d ago
DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction
Benzinga · 1d ago
DiaMedica doses first patients in Phase 2 fetal growth restriction trial of DM199
PUBT · 1d ago
DIAMEDICA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 TRIAL OF DM199 FOR THE TREATMENT OF FETAL GROWTH RESTRICTION
Reuters · 1d ago
Weekly Report: what happened at DMAC last week (0615-0619)?
Weekly Report · 2d ago
Craig-Hallum Remains a Buy on Diamedica Therapeutics (DMAC)
TipRanks · 6d ago
BUZZ-DiaMedica rises after FDA feedback clears path for preeclampsia drug study
Reuters · 06/16 12:53
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.